Abstract
Panobinostat is a radiosensitizing agent and targets the epigenetics of malignancy. This phase I study evaluated the safety and efficacy of combining oral panobinostat with radiotherapy (RT) or chemoradiotherapy (CRT) in patients with inoperable stage III non-small-cell lung cancer. This study had a parallel dose-escalating design combining oral panobinostat twice a week (dose escalations 20, 30, 45 mg) with either palliative RT (group A) or radical CRT (group B) using a standard chemotherapy protocol of cisplatin and etoposide. In group A (RT), nine recruited patients received treatment with oral panobinostat (doses 20, 30, 45 mg) with RT. Two serious adverse events, rapid atrial fibrillation and tracheo-oesophageal fistula, were not attributable to study treatment. The most common grade 3/4 toxicities were thrombocytopenia and lymphopenia, which resolved promptly after cessation of panobinostat. The disease control rate was 66%, the progression-free survival was 3 months and the median overall survival was 9 months. In group B (CRT), panobinostat dose was not escalated beyond 20 mg because of infection-related complications. Serious adverse events included opportunistic infection associated with treatment-related lymphopenia ...Continue Reading
References
Oct 1, 1995·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·R P AbrattD G Salton
May 9, 1998·Journal of Clinical Microbiology·W TeeM L Dyall-Smith
Aug 31, 2002·BMJ : British Medical Journal·Stephen J FalkUNKNOWN Medical Research Council Lung Cancer Working Party
Mar 29, 2003·Journal of Clinical Pathology·C PienaarJ D D Pitout
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stein SundstrømStein Kaasa
May 12, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel FarrayKathy S Albain
Aug 30, 2005·The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases·Carina SecchiEverton Inamine
Feb 8, 2006·Oncogene·T C Karagiannis, A El-Osta
Oct 6, 2007·Chest·James R JettUNKNOWN American College of Chest Physicians
Nov 13, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nasser HannaUNKNOWN US Oncology
Nov 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David R SpigelF Anthony Greco
Jul 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nobuyuki YamamotoMasahiro Fukuoka
Feb 5, 2011·Blood·Mark J BishtonRicky W Johnstone
Feb 25, 2011·Future Oncology·K Ted ThurnPamela N Munster
Apr 13, 2011·Investigational New Drugs·Akira FukutomiNobuyuki Yamamoto
Oct 4, 2011·Investigational New Drugs·Sachi MoritaYuichi Ando
Mar 3, 2012·Experimental Hematology·Camelia Iancu-RubinRonald Hoffman
Aug 2, 2012·Cancer Chemotherapy and Pharmacology·Suzanne F JonesHoward A Burris
Feb 26, 2013·Cancer Investigation·Jian L CampianStuart A Grossman
Nov 5, 2013·Anti-cancer Drugs·Marije SlingerlandHans Gelderblom
Citations
May 14, 2016·Acta Oncologica·N BernardsV E P P Lemmens
Oct 19, 2016·Clinical Epigenetics·Angel R de Lera, A Ganesan
Apr 14, 2017·Cell Death & Disease·Lihui WangChunfu Wu
Feb 25, 2017·Journal of Pediatric Hematology/oncology·Zhihong J WangMiller Steven
May 17, 2017·Scientific Reports·Leleesha SamaraweeraHayley M McDaid
Jul 2, 2017·Clinical Pharmacokinetics·Mathilde Van VeggelPaul Hamberg
Feb 11, 2021·Cancers·Robert JenkeThomas Büch
Jan 8, 2017·Biomaterials·Leoni A Kunz-SchughartSuman Pokhrel
Jun 10, 2021·Clinical Epigenetics·Catarina Macedo-SilvaLucia Altucci